Wortmannin inhibits K562 leukemic cells by regulating PI3k/Akt channel in vitro

Qing Wu1, Yan Chen, Guohui Cui

  • 1Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, China. wuqing1221@21cn.cn

Insights

Wortmannin effectively inhibits K562 leukemia cell growth and induces apoptosis by down-regulating key survival pathways, including PI3K/Akt and NF-kappaB signaling.

Area of Science:

  • Pharmacology
  • Molecular Biology
  • Cancer Research

Background:

  • Leukemia, specifically K562 cell line, presents a significant challenge in cancer therapy.
  • Understanding the molecular mechanisms underlying drug action is crucial for developing effective treatments.

Purpose of the Study:

  • To investigate the inhibitory effects of wortmannin on K562 leukemia cells.
  • To elucidate the underlying molecular mechanisms, focusing on apoptosis induction and signaling pathway modulation.

Main Methods:

  • K562 cells were treated with varying concentrations of wortmannin.
  • Cell viability was assessed using MTT assay.
  • Apoptosis was detected via flow cytometry and transmission electron microscopy (TEM).
  • Protein and gene expression of key signaling molecules (p-Akt, NF-kappaBp65, IKK-kappaB) were analyzed using Western blotting and RT-PCR.

Main Results:

  • Wortmannin demonstrated significant time- and dose-dependent inhibition of K562 cell proliferation.
  • The drug induced apoptosis in K562 cells, evidenced by morphological changes and Annexin-V FITC/PI staining.
  • Wortmannin treatment led to the degradation of p-Akt, NF-kappaBp65, and IKK-kappaB at both protein and transcriptional levels, without affecting total Akt expression.

Conclusions:

  • Wortmannin inhibits K562 leukemia cell proliferation and induces apoptosis.
  • These effects are likely mediated through the downregulation of survival signaling pathways, specifically the PI3K/Akt and NF-kappaB pathways.

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...